Nov 28, 2023
Press releases
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
Evaxion proudly announces the presentation of its novel precision vaccine concept at the 65th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, from December 9-12, 2023.
Nov 27, 2023
Publications
Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence
Publication: mBio
Authors: Sunita Gulati, Andreas Holm Mattsson, Sophie Schussek, Bo Zheng, Rosane B. DeOliveira, Jutamas Shaughnessy, Lisa A. Lewis, Peter A. Rice, Pär Comstedt, Sanjay Ram
Nov 15, 2023
Press releases
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
Evaxion presents for the first time its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany.
Nov 8, 2023
Presentations
Presentation of Latest Confirmatory EVX01 Clinical Data with Key Opinion Leader Adnan Khattak
In this presentation, Professor Adnan Khattak will set the scene by introducing participants to the medical field of malignant melanoma and the need that Evaxion’s personalized cancer vaccines is trying to meet.
Nov 6, 2023
Press releases
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
Evaxion hosted an online webinar featuring Key Opinion Leader (KOL) and study’s Principal Investigator (PI), Professor Adnan Khattak. The webinar took place on November 8 at 11:30 a.m. EST
Oct 31, 2023
Press releases
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
Evaxion announces initial results from the EVX-01 Phase 2 clinical trial, confirming previous successful Phase 1 findings
Oct 26, 2023
Press releases
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
Evaxion is proud to announce that it will be presenting clinical readouts on its two personalized cancer vaccine trials at SITC’s 38th annual meeting, taking place in San Diego, California from November 1-5, 2023.
Oct 5, 2023
Press releases
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Evaxion received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”).
Sep 21, 2023
Presentations
Connecting the dots: EDEN validation and partnerships
Watch Evaxion founder Andreas Holm Mattson talk about EDEN validation and partnerships
Sep 20, 2023
Press releases
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
Evaxion announced a collaboration with Afrigen Biologics (Afrigen)
Sep 18, 2023
Press releases
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
Evaxion announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen.
Sep 11, 2023
Press releases
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDEN.
Evaxion Media kit
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.